• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探究胰腺癌碳离子放疗中LETd优化策略:使用人体模型的剂量学研究

Investigating LETd optimization strategies in carbon ion radiotherapy for pancreatic cancer: a dosimetric study using an anthropomorphic phantom.

作者信息

Baltazar Filipa, Longarino Friderike K, Stengl Christina, Liermann Jakob, Mein Stewart, Debus Jürgen, Tessonnier Thomas, Mairani Andrea

机构信息

Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg, Germany.

Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

出版信息

Med Phys. 2025 Mar;52(3):1746-1757. doi: 10.1002/mp.17569. Epub 2024 Dec 10.

DOI:10.1002/mp.17569
PMID:39656067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11880654/
Abstract

BACKGROUND

Clinical carbon ion beams offer the potential to overcome hypoxia-induced radioresistance in pancreatic tumors, due to their high dose-averaged Linear Energy Transfer (LETd), as previous studies have linked a minimum LETd within the tumor to improved local control. Current clinical practices at the Heidelberg Ion-Beam Therapy Center (HIT), which use two posterior beams, do not fully exploit the LETd advantage of carbon ions, as the high LETd is primarily focused on the beams' distal edges. Different LETd-boosting strategies, such as Spot-scanning Hadron Arc (SHArc), could enhance LETd distribution by concentrating high-LETd values in potential hypoxic tumor cores while sparing organs at risk.

PURPOSE

This study aims to investigate and verify different LETd-boosting strategies using an anthropomorphic pancreas phantom.

METHODS

Various LETd-boosting strategies were investigated for a cylindrical and a pancreas-shaped target in an anthropomorphic pancreas phantom. Treatment plans were optimized using single field optimization (SFO) or multi field optimization (MFO), with objective functions based on either physical dose (Phys), relative biological effectiveness (RBE)-weighted dose, or a combination of RBE and LETd-based objectives (LETopt). The LETd-boosting planning strategies were optimized with the goal of increasing the minimum LETd in the tumor without compromising its homogeneous dose coverage. Beam configurations investigated included the two-beam in-house clinical standard (2-SFO, 2-SFO and 2-MFO), a three-beam configuration (3-MFO and 3-MFO) and SHArc (SHArc, SHArc and SHArc) using step-and-shoot delivery. The different plans were verified using an anthropomorphic pancreas phantom at HIT and compared to treatment planning system (TPS) predictions.

RESULTS

All investigated LETd-boosting strategies altered the LETd distribution while meeting optimization goals and constraints, resulting in varying degrees of LETd enhancement. For the cylindrical volume, the SHArc plan resulted in the highest LETd concentration in the tumor core, with the minimum LETd in the GTV scaling up to 91 keV/µm. For the pancreas-shaped volume, however, the 3-MFO achieved a higher minimum LETd in the GTV than SHArc (75.6 and 62.3 keV/µm, respectively). When combining SHArc with LETd optimization, a minimum LETd of 76.3 keV/µm was achieved, suggesting a potential benefit from this combined approach. Most dosimetric verifications showed dose deviations to the TPS within a 5% range, for both beam-per-beam and total dose. LETd-optimized and SHArc plans exhibited slightly higher mean dose deviations (2.0%-4.6%) compared to the standard RBE-based plans (<1.5%).

CONCLUSION

This study demonstrated the feasibility of enhancing LETd in pancreatic tumors using carbon ion arc delivery coupled with LETd optimization. The possibility of delivering these plans was verified through irradiation of an anthropomorphic pancreas phantom, which showed agreement between dose measurements and predictions.

摘要

背景

临床碳离子束有潜力克服胰腺肿瘤中因缺氧导致的放射抗性,这归因于其高剂量平均线能量转移(LETd),因为先前的研究已将肿瘤内的最低LETd与改善局部控制联系起来。海德堡离子束治疗中心(HIT)目前的临床实践使用两束后向射束,并未充分利用碳离子的LETd优势,因为高LETd主要集中在射束的远端边缘。不同的LETd增强策略,如点扫描强子弧(SHArc),可以通过将高LETd值集中在潜在的缺氧肿瘤核心同时保护危及器官,来增强LETd分布。

目的

本研究旨在使用拟人化胰腺体模研究并验证不同的LETd增强策略。

方法

在拟人化胰腺体模中,针对圆柱形和胰腺形状的靶区研究了各种LETd增强策略。使用单野优化(SFO)或多野优化(MFO)对治疗计划进行优化,目标函数基于物理剂量(Phys)、相对生物效应(RBE)加权剂量或基于RBE和LETd的目标组合(LETopt)。LETd增强计划策略的优化目标是在不影响肿瘤均匀剂量覆盖的情况下提高肿瘤内的最低LETd。研究的射束配置包括两束内部临床标准配置(2-SFO、2-SFO和2-MFO)、三束配置(3-MFO和3-MFO)以及使用步进式射束投照的SHArc(SHArc、SHArc和SHArc)。在HIT使用拟人化胰腺体模对不同计划进行验证,并与治疗计划系统(TPS)预测结果进行比较。

结果

所有研究的LETd增强策略在满足优化目标和约束条件的同时改变了LETd分布,导致LETd有不同程度的增强。对于圆柱形体积,SHArc计划在肿瘤核心产生了最高的LETd浓度,GTV中的最低LETd扩大到91 keV/μm。然而,对于胰腺形状的体积,3-MFO在GTV中实现了比SHArc更高的最低LETd(分别为75.6和62.3 keV/μm)。当将SHArc与LETd优化相结合时,实现了76.3 keV/μm的最低LETd,表明这种联合方法可能带来益处。大多数剂量验证显示,无论是逐束剂量还是总剂量,与TPS的剂量偏差在5%范围内。与基于标准RBE的计划(<1.5%)相比,LETd优化和SHArc计划表现出略高的平均剂量偏差(2.0%-4.6%)。

结论

本研究证明了使用碳离子弧形投照结合LETd优化来增强胰腺肿瘤中LETd的可行性。通过对拟人化胰腺体模进行照射验证了实施这些计划的可能性,照射结果显示剂量测量与预测结果相符。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170f/11880654/10d58ec9020d/MP-52-1746-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170f/11880654/5303e0b3d35e/MP-52-1746-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170f/11880654/134d8be0c25a/MP-52-1746-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170f/11880654/10d58ec9020d/MP-52-1746-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170f/11880654/5303e0b3d35e/MP-52-1746-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170f/11880654/134d8be0c25a/MP-52-1746-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170f/11880654/10d58ec9020d/MP-52-1746-g001.jpg

相似文献

1
Investigating LETd optimization strategies in carbon ion radiotherapy for pancreatic cancer: a dosimetric study using an anthropomorphic phantom.探究胰腺癌碳离子放疗中LETd优化策略:使用人体模型的剂量学研究
Med Phys. 2025 Mar;52(3):1746-1757. doi: 10.1002/mp.17569. Epub 2024 Dec 10.
2
Dose averaged linear energy transfer optimization for large sacral chordomas in carbon ion therapy.碳离子放疗中骶骨脊索瘤的剂量平均线性能量传递优化。
Med Phys. 2024 Jun;51(6):3950-3960. doi: 10.1002/mp.17102. Epub 2024 May 2.
3
Spot-scanning hadron arc (SHArc) therapy: A proof of concept using single- and multi-ion strategies with helium, carbon, oxygen, and neon ions.点扫描强子弧形(SHArc)治疗:使用氦、碳、氧和氖离子的单离子和多离子策略的概念验证。
Med Phys. 2022 Sep;49(9):6082-6097. doi: 10.1002/mp.15800. Epub 2022 Jul 11.
4
Biological Dose Optimization for Particle Arc Therapy Using Helium and Carbon Ions.利用氦离子和碳离子进行粒子弧形治疗的生物学剂量优化。
Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):334-348. doi: 10.1016/j.ijrobp.2022.04.025. Epub 2022 Apr 29.
5
Validation of linear energy transfer computed in a Monte Carlo dose engine of a commercial treatment planning system.验证商业治疗计划系统中蒙特卡罗剂量引擎计算的线性能量传递。
Phys Med Biol. 2020 Jan 17;65(2):025006. doi: 10.1088/1361-6560/ab5e97.
6
Impact of porous lung substitute on linear energy transfer (LET) assessed via Monte Carlo simulation and CR-39 measurement with a carbon-ion beam.通过蒙特卡罗模拟和碳离子束CR-39测量评估多孔肺替代物对线性能量传递(LET)的影响。
Med Phys. 2025 Apr;52(4):2593-2605. doi: 10.1002/mp.17671. Epub 2025 Feb 5.
7
Proton monoenergetic arc therapy (PMAT) to enhance LETd within the target.质子单能弧治疗(PMAT)以提高靶区内的 LETd。
Phys Med Biol. 2020 Aug 19;65(16):165006. doi: 10.1088/1361-6560/ab9455.
8
First Dosimetric and Biological Verification for Spot-Scanning Hadron Arc Radiation Therapy With Carbon Ions.碳离子点扫描强子弧形放射治疗的首次剂量学和生物学验证
Adv Radiat Oncol. 2024 Sep 11;9(12):101611. doi: 10.1016/j.adro.2024.101611. eCollection 2024 Dec.
9
Quantitative analysis of dose-averaged linear energy transfer (LET ) robustness in pencil beam scanning proton lung plans.笔形束扫描质子肺部计划中剂量平均线性能量传递(LET)稳健性的定量分析。
Med Phys. 2022 May;49(5):3444-3456. doi: 10.1002/mp.15569. Epub 2022 Mar 7.
10
Spot-Scanning Hadron Arc (SHArc) Therapy: A Study With Light and Heavy Ions.点扫描强子弧形(SHArc)疗法:一项关于轻离子和重离子的研究。
Adv Radiat Oncol. 2021 Feb 4;6(3):100661. doi: 10.1016/j.adro.2021.100661. eCollection 2021 May-Jun.

引用本文的文献

1
HyperSHArc: Single-Isocenter Stereotactic Radiosurgery of Multiple Brain Metastases Using Proton, Helium, and Carbon Ion Arc Therapy.HyperSHArc:使用质子、氦离子和碳离子弧形治疗对多发脑转移瘤进行单等中心立体定向放射外科治疗。
Adv Radiat Oncol. 2025 Mar 17;10(5):101763. doi: 10.1016/j.adro.2025.101763. eCollection 2025 May.

本文引用的文献

1
First Dosimetric and Biological Verification for Spot-Scanning Hadron Arc Radiation Therapy With Carbon Ions.碳离子点扫描强子弧形放射治疗的首次剂量学和生物学验证
Adv Radiat Oncol. 2024 Sep 11;9(12):101611. doi: 10.1016/j.adro.2024.101611. eCollection 2024 Dec.
2
Study of Simultaneous Integrated Boost Carbon-Ion Radiotherapy for Locally Advanced Pancreatic Cancer.局部晚期胰腺癌同步整合加量碳离子放疗研究。
Anticancer Res. 2024 Sep;44(9):3821-3828. doi: 10.21873/anticanres.17208.
3
Particle arc therapy: Status and potential.粒子弧形治疗:现状与潜能。
Radiother Oncol. 2024 Oct;199:110434. doi: 10.1016/j.radonc.2024.110434. Epub 2024 Jul 14.
4
Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.剂量平均线性能量传递优化碳离子放射治疗头颈部肿瘤。
Radiother Oncol. 2024 May;194:110180. doi: 10.1016/j.radonc.2024.110180. Epub 2024 Feb 24.
5
A phantom to simulate organ motion and its effect on dose distribution in carbon ion therapy for pancreatic cancer.一种用于模拟器官运动及其对胰腺癌碳离子治疗中剂量分布影响的模体。
Phys Med Biol. 2023 Dec 11;68(24). doi: 10.1088/1361-6560/ad0902.
6
The LET trilemma: Conflicts between robust target coverage, uniform dose, and dose-averaged LET in carbon therapy.碳离子治疗中的 LET 三重困境:强大的靶区覆盖、均匀剂量和剂量平均 LET 之间的冲突。
Med Phys. 2023 Dec;50(12):7338-7348. doi: 10.1002/mp.16771. Epub 2023 Oct 11.
7
Carbon Ions for Hypoxic Tumors: Are We Making the Most of Them?用于缺氧肿瘤的碳离子:我们是否充分利用了它们?
Cancers (Basel). 2023 Sep 9;15(18):4494. doi: 10.3390/cancers15184494.
8
Development and validation of MonteRay, a fast Monte Carlo dose engine for carbon ion beam radiotherapy.用于碳离子束放射治疗的快速蒙特卡罗剂量引擎MonteRay的开发与验证。
Med Phys. 2024 Feb;51(2):1433-1449. doi: 10.1002/mp.16754. Epub 2023 Sep 25.
9
Carbon-ion radiotherapy (CIRT) as treatment of pancreatic cancer at HIT: initial radiation plan analysis of the prospective phase II PACK-study.碳离子放疗(CIRT)用于哈尔滨医科大学附属肿瘤医院胰腺癌的治疗:前瞻性II期PACK研究的初始放疗计划分析
Radiother Oncol. 2023 Nov;188:109872. doi: 10.1016/j.radonc.2023.109872. Epub 2023 Aug 25.
10
Clinical benefit of range uncertainty reduction in proton treatment planning based on dual-energy CT for neuro-oncological patients.基于双能 CT 的神经肿瘤患者质子治疗计划中范围不确定性降低的临床获益。
Br J Radiol. 2023 Sep;96(1149):20230110. doi: 10.1259/bjr.20230110. Epub 2023 Jul 26.